Please login to the form below

Not currently logged in

FDA approves Merck’s insomnia drug

Belsomra is first orexin receptor antagonist available in US
Merck and Co - US headquarters

People with the sleep disorder insomnia now have access to a new treatment option after the FDA approved Merck & Co's Belsomra.

The drug, which contains the active ingredient suvorexant, is the first medicine approved in the US that affects the signalling action of orexin, a brain chemical involved in regulating a person's sleep cycle.

The approval covers all types of insomnia, which can range from mild to severe and is defined by an individual's trouble in falling or staying asleep.   

To cover the varying severity of the disorder, Belsomra is available in four different strengths – 5mg, 10mg, 15mg and 20mg.

The drug should be taken no more than once per night and with at least seven hours remaining before the planned time of waking in order to reduce the risk of drowsiness during morning activities, such as driving. Indeed, the FDA recommends anyone on the highest does should be cautioned against next-day driving or activities requiring full mental alertness.

Dr David Michelson, VP, neurosciences, Merck Research Laboratories, commendted: “Belsomra is the result of more than a decade of Merck research in neuroscience and provides tangible evidence of our long-standing commitment to innovation."

This research included three clinical trials involving more than 500 participants during which patients taking Belsomra fell asleep faster and spent less time awake during the remainder of the night compared to people taking placebo.

Article by
Thomas Meek

14th August 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...